Results 121 to 130 of about 39,319 (205)

Digital assessment of real-world walking in people with impaired mobility: How many hours and days are needed? [PDF]

Int J Behav Nutr Phys Act
Buekers J, Chernova J, Koch S, Marchena J, Lemos J, Becker C, Bonci T, Braun J, Brittain G, Buckley E, Caulfield B, Del Din S, Demeyer H, Frei A, Gazit E, Hausdorff JM, Ionescu A, Jansen CP, Klenk J, Long M, Sharrack B, Singleton D, Troosters T, Yarnall AJ, Rochester L, Garcia-Aymerich J.   +25 more
europepmc   +1 more source

Tiscover: Destination management system pioneer [PDF]

, 2008
Alford, Philip, Karcher, Karsten
core  

Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study. [PDF]

Eye (Lond)
Peto T, Pearce I, Talks J, de Salvo G, Patel PJ, de Silva SR, Gale RP, Sivaprasad S, Varma D, Reynolds R, Bailey C, Downey L, Kiire C, Chi GC, Dodds M, James N, Downey AK, Dayal P.   +17 more
europepmc   +1 more source

Anchor-based evaluation of digital motor biomarkers from a 2-year observation in 100 patients with multiple sclerosis. [PDF]

J Neurol
Ellinghaus CA, Röhling HM, Dorsch EM, Sperber PS, Arsenova R, Buenrostro GS, Rekers S, Usnich T, Schindler P, Kroneberg D, Bellmann-Strobl J, Oertel FC, Brandt AU, Weygandt M, Paul F, Piper SK, Schmitz-Hübsch T.   +16 more
europepmc   +1 more source

Low-valent cobalt catalyzed direct dehydroxylative cross-coupling of benzyl alcohols with aryl-chlorides. [PDF]

Chem Sci
Shinde PS, Shinde VS, Rueping M.
europepmc   +1 more source

Omentin-1 protects against endothelial dysfunction through the AMPK/KLF2/eNOS pathway in adult rat offspring exposed to maternal diabetes. [PDF]

Nutr Diabetes
Wang C, Wang Q, Mai H.
europepmc   +1 more source

Evaluating the long-term predictive value of macular thickness fluctuations on diabetic macular oedema response to anti-VEGF treatment. [PDF]

Eye (Lond)
Alam T, Das N, Maatouk C, Zhao A, Singh RP, Talcott KE.   +5 more
europepmc   +1 more source

Cost-effectiveness of anti-vascular endothelial growth factor and macular laser treatments for people with centre-involving diabetic macular oedema and central retinal thickness of at least 400 micrometres. [PDF]

Eye (Lond)
Luckham K, Tebbs H, Dadswell C, Yosef A, Claxton L, Kelley K, Taske N, Burgess PI, Dinah C, Lois N, Mohiuddin S.   +10 more
europepmc   +1 more source

Differentiating treatment episodes from gaps in eyes with diabetic macular oedema. [PDF]

Br J Ophthalmol
Hashimoto Y, Hunt AR, Silva R, Witmer A, Kheir WJ, Viola F, Arrazola M, Mahgoub MM, Pollreisz A, Harvey Z, Barthelmes D, Gillies MC.   +11 more
europepmc   +1 more source

Impact of anti-VEGF treatment for diabetic macular oedema on progression to proliferative diabetic retinopathy: data-driven insights from a multicentre study. [PDF]

BMJ Open Ophthalmol
Olvera-Barrios A, Lilaonitkul W, Heeren TFC, Rozenberg A, Thomas D, Warwick A, Soomro T, Alsaedi A, Schwartz R, Chakravarthy U, Eleftheriadis H, Ghanchi F, Patwardhan A, Taylor P, Tufail A, A Egan C, UK DR EHR Users group, UK DR EMR Users group.   +17 more
europepmc   +1 more source